# A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Source: https://onco.cc/trials/nct05516914/  
OnCo record `nct05516914` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Alcestobart run by Nanjing Leads Biolabs Co.,Ltd, completed.

## Summary

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors is a phase 1/2 interventional study registered as NCT05516914 by Nanjing Leads Biolabs Co.,Ltd, with 98 participants enrolled, started 2022-09-01. Conditions recorded: Malignant Tumors. Interventions recorded: LBL-007 Injection, Tislelizumab Injection, Cisplatin Injection, Gemcitabine Hydrochloride for Injection and Docetaxel injection.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05516914
- Phase: 1/2
- Setting: A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Tislelizumab in the Treatment of Malignancies
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 98

## Sources

- ClinicalTrials.gov NCT05516914: https://clinicaltrials.gov/study/NCT05516914

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Alcestobart](https://onco.cc/drugs/alcestobart/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct05516914.json